Tokyo/New Delhi: Japanese drug major Daiichi
Sankyo said on Monday a US Court has ruled in its favour in a patent litigation related to the anti-hypertensive drug, Benicar, against Mylan Inc and its Indian subsidiary, Matrix
Laboratories.
"...US District Court in New Jersey has issued a decision
in our US patent litigation against Mylan upholding the
validity of our patent covering the Benicar, Benicar HCT and
Azor products," Daiichi Sankyo said in a statement.
The company has initiated the process of litigation
against Mylan and Matrix in response to the Abbreviated New
Drug Application (ANDA) filed by Mylan with the US health
regulator, Food and Drug Administration (FDA), last year,
seeking its nod to market generic versions of those products.
"We had initiated the litigation against Mylan in
response to ANDA filed by Mylan seeking to market generic
versions of those products before the expiration of our
patent, which expires in 2016," Daiichi Sankyo said.
The Japanese company had filed a litigation alleging
violation of its intellectual property right for Olmesartan
Medoxomil, an active pharmaceutical ingredient used in the
preparation of the drug Benicar, Benicar HCT, and Azor.
Bureau Report
First Published: Monday, August 03, 2009, 23:46